RU2017145348A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017145348A3 RU2017145348A3 RU2017145348A RU2017145348A RU2017145348A3 RU 2017145348 A3 RU2017145348 A3 RU 2017145348A3 RU 2017145348 A RU2017145348 A RU 2017145348A RU 2017145348 A RU2017145348 A RU 2017145348A RU 2017145348 A3 RU2017145348 A3 RU 2017145348A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15171785.7 | 2015-06-12 | ||
| EP15171785 | 2015-06-12 | ||
| PCT/EP2016/063429 WO2016198682A1 (en) | 2015-06-12 | 2016-06-13 | Selective pyy compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017145348A RU2017145348A (ru) | 2019-07-12 |
| RU2017145348A3 true RU2017145348A3 (enExample) | 2019-09-09 |
| RU2726777C2 RU2726777C2 (ru) | 2020-07-15 |
Family
ID=53404384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017145348A RU2726777C2 (ru) | 2015-06-12 | 2016-06-13 | Селективные соединения пептида yy и их применения |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10005824B2 (enExample) |
| EP (1) | EP3307768B1 (enExample) |
| JP (1) | JP6731958B2 (enExample) |
| KR (1) | KR102476550B1 (enExample) |
| CN (1) | CN107849110B (enExample) |
| AR (1) | AR104984A1 (enExample) |
| AU (1) | AU2016275735B2 (enExample) |
| BR (1) | BR112017025108A2 (enExample) |
| CA (1) | CA2988500A1 (enExample) |
| ES (1) | ES3019234T3 (enExample) |
| IL (1) | IL255781B (enExample) |
| MA (1) | MA43205A (enExample) |
| MX (1) | MX392572B (enExample) |
| MY (1) | MY187047A (enExample) |
| RU (1) | RU2726777C2 (enExample) |
| SA (1) | SA517390445B1 (enExample) |
| TW (1) | TWI694082B (enExample) |
| WO (1) | WO2016198682A1 (enExample) |
| ZA (1) | ZA201707782B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| WO2015071355A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| JP2019518065A (ja) | 2016-06-14 | 2019-06-27 | ピュアサークル ユーエスエー インコーポレイテッド | ステビオール配糖体組成物、製造方法および使用 |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| TWI749381B (zh) | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| EP4009957B1 (en) * | 2019-08-07 | 2023-10-11 | Novo Nordisk A/S | Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| KR20220100925A (ko) | 2019-11-11 | 2022-07-18 | 베링거 인겔하임 인터내셔날 게엠베하 | Npy2 수용체 작용제 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CA3175725A1 (en) | 2020-04-17 | 2021-10-21 | William Blackwell | Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use |
| WO2022029231A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
| IL302745A (en) * | 2020-11-09 | 2023-07-01 | Embark Biotech Aps | Compounds and their use in the treatment of tachykinin receptor mediated disorders |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4433093A1 (en) | 2021-11-15 | 2024-09-25 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| KR20240110876A (ko) * | 2021-11-30 | 2024-07-16 | 닛산 가가쿠 가부시키가이샤 | 하이드록시계피산 유도체를 갖는 레지스트 하층막 형성용 조성물 |
| EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| JP2025526148A (ja) | 2022-08-18 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療 |
| CN117603364A (zh) * | 2022-09-30 | 2024-02-27 | 广西医科大学附属肿瘤医院 | 一类GLP-1/glucagon/Y2受体三重激动剂及其应用 |
| AR134636A1 (es) * | 2023-12-12 | 2026-02-04 | Carmot Therapeutics Inc | Compuestos peptídicos híbridos que tienen un residuo de lisina modificado |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1124927A (zh) * | 1993-03-29 | 1996-06-19 | 辛辛那提大学 | Yy肽类似物及其应用 |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| WO1998020885A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| ATE232200T1 (de) | 1998-06-08 | 2003-02-15 | Schering Corp | Neuropeptid y5-rezeptorantagonisten |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| EP2123293A3 (en) * | 2000-12-14 | 2010-09-08 | Amylin Pharmaceuticals, Inc. | Peptide YY and petide YY agonists for treatment of metabolic disorders |
| US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| ES2320979T3 (es) | 2001-09-24 | 2009-06-01 | Imperial Innovations Limited | Pyy-36 para la reduccion o prevencion de la obesidad. |
| US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US7811989B2 (en) | 2003-01-17 | 2010-10-12 | Ipsen Pharma S.A.S. | Peptide YY analogs |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| KR20140011431A (ko) | 2004-02-11 | 2014-01-28 | 아밀린 파마슈티칼스, 엘엘씨. | 선택가능한 특성을 갖는 하이브리드 폴리펩티드 |
| EP1789440A4 (en) | 2004-02-11 | 2008-03-12 | Amylin Pharmaceuticals Inc | REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM |
| CN1933848A (zh) | 2004-03-17 | 2007-03-21 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y2选择性受体激动剂 |
| EP2272524A3 (en) | 2004-03-17 | 2011-02-02 | 7TM Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
| WO2005089790A2 (en) | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2/y4 selective receptor agonists for therapeutic interventions |
| DK2060266T3 (da) | 2004-03-17 | 2011-11-14 | 7Tm Pharma As | Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| ES2542228T3 (es) | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| WO2006020207A2 (en) | 2004-07-19 | 2006-02-23 | University Of Cincinnati | Compounds for control of appetite |
| ES2323141T3 (es) * | 2004-08-12 | 2009-07-07 | Quest Pharmaceutical Services | Composiciones farmaceuticas para el suministro por liberacion controlada de compuestos biologicamente activos. |
| WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| WO2007008778A2 (en) | 2005-07-11 | 2007-01-18 | Nastech Pharmaceutical Company Inc. | Formulations for enhanced mucosal delivery of pyy |
| CN101222942A (zh) | 2005-07-18 | 2008-07-16 | 诺沃-诺迪斯克有限公司 | 用于治疗肥胖的肽 |
| EP1922336B1 (en) * | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| CN101268099A (zh) | 2005-09-21 | 2008-09-17 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y4选择性受体激动剂 |
| EP1934245B1 (en) | 2005-09-21 | 2011-07-13 | 7TM Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
| EP1962959B1 (en) | 2005-12-07 | 2012-03-14 | F. Hoffmann-La Roche AG | Neuropeptide-2 receptor-agonists |
| WO2007068718A1 (en) | 2005-12-14 | 2007-06-21 | Novo Nordisk A/S | Polypeptide protracting tags |
| US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| EP2054073B1 (en) * | 2006-07-11 | 2014-11-26 | Foresee Pharmaceuticals, Inc. | Pharmaceutical compositions for sustained release delivery of peptides |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
| US20100022446A1 (en) | 2007-01-18 | 2010-01-28 | Novo Nordisk A/S | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
| US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
| BRPI0814629A2 (pt) | 2007-07-09 | 2015-01-27 | Imp Innovations Ltd | Compostos e seus efeitos sobre o comportamento alimentar |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100286029A1 (en) * | 2007-09-11 | 2010-11-11 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| RU2504550C2 (ru) * | 2008-05-16 | 2014-01-20 | Ново Нордиск А/С | Длительно действующие агонисты рецепторов y2 и(или) y4 |
| US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
| BRPI0921230A2 (pt) | 2008-11-05 | 2018-10-30 | Hoffmann La Roche | agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo. |
| MX2011008774A (es) | 2009-02-20 | 2011-10-24 | Ipsen Pharma Sas | Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y. |
| CN102573888A (zh) * | 2009-09-18 | 2012-07-11 | 诺和诺德公司 | 长效y2 受体激动剂 |
| JP2013507414A (ja) | 2009-10-13 | 2013-03-04 | エフ．ホフマン−ラ ロシュ アーゲー | 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト |
| EP2498800A1 (en) | 2009-11-13 | 2012-09-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| WO2011131646A1 (en) | 2010-04-20 | 2011-10-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| EP2855517A1 (en) | 2012-05-29 | 2015-04-08 | Novo Nordisk A/S | Pancreatic polypeptide compounds and use |
| EP2992008B1 (en) | 2013-05-02 | 2019-04-10 | GlaxoSmithKline Intellectual Property Development Limited | Therapeutic peptides |
| US10583172B2 (en) * | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| WO2015071355A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
-
2016
- 2016-06-13 MX MX2017015105A patent/MX392572B/es unknown
- 2016-06-13 BR BR112017025108A patent/BR112017025108A2/pt not_active Application Discontinuation
- 2016-06-13 ES ES16734567T patent/ES3019234T3/es active Active
- 2016-06-13 TW TW105118511A patent/TWI694082B/zh not_active IP Right Cessation
- 2016-06-13 AU AU2016275735A patent/AU2016275735B2/en not_active Ceased
- 2016-06-13 EP EP16734567.7A patent/EP3307768B1/en active Active
- 2016-06-13 AR ARP160101755A patent/AR104984A1/es unknown
- 2016-06-13 MA MA043205A patent/MA43205A/fr unknown
- 2016-06-13 JP JP2017564450A patent/JP6731958B2/ja active Active
- 2016-06-13 WO PCT/EP2016/063429 patent/WO2016198682A1/en not_active Ceased
- 2016-06-13 RU RU2017145348A patent/RU2726777C2/ru active
- 2016-06-13 MY MYPI2017704318A patent/MY187047A/en unknown
- 2016-06-13 KR KR1020177037622A patent/KR102476550B1/ko active Active
- 2016-06-13 CN CN201680045277.3A patent/CN107849110B/zh active Active
- 2016-06-13 CA CA2988500A patent/CA2988500A1/en not_active Withdrawn
-
2017
- 2017-06-28 US US15/635,456 patent/US10005824B2/en active Active
- 2017-11-16 ZA ZA2017/07782A patent/ZA201707782B/en unknown
- 2017-11-20 IL IL255781A patent/IL255781B/en unknown
- 2017-11-30 SA SA517390445A patent/SA517390445B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA517390445B1 (ar) | 2020-12-21 |
| JP6731958B2 (ja) | 2020-07-29 |
| EP3307768B1 (en) | 2025-01-29 |
| US20170313750A1 (en) | 2017-11-02 |
| AU2016275735B2 (en) | 2020-02-06 |
| CA2988500A1 (en) | 2016-12-15 |
| TW201710284A (zh) | 2017-03-16 |
| ES3019234T3 (en) | 2025-05-20 |
| MX2017015105A (es) | 2018-05-07 |
| CN107849110B (zh) | 2021-11-26 |
| BR112017025108A2 (pt) | 2018-07-31 |
| WO2016198682A1 (en) | 2016-12-15 |
| US10005824B2 (en) | 2018-06-26 |
| RU2017145348A (ru) | 2019-07-12 |
| MY187047A (en) | 2021-08-27 |
| EP3307768C0 (en) | 2025-01-29 |
| EP3307768A1 (en) | 2018-04-18 |
| MX392572B (es) | 2025-03-24 |
| TWI694082B (zh) | 2020-05-21 |
| KR20180019616A (ko) | 2018-02-26 |
| RU2726777C2 (ru) | 2020-07-15 |
| JP2018522843A (ja) | 2018-08-16 |
| IL255781B (en) | 2021-10-31 |
| KR102476550B1 (ko) | 2022-12-13 |
| AR104984A1 (es) | 2017-08-30 |
| MA43205A (fr) | 2018-09-19 |
| CN107849110A (zh) | 2018-03-27 |
| IL255781A (en) | 2018-04-30 |
| ZA201707782B (en) | 2019-08-28 |
| AU2016275735A1 (en) | 2017-12-07 |